• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Seminars in Respiratory and Critical Care Medicine >Imaging assessment of lung tumor angiogenesis: Insights and innovations
【24h】

Imaging assessment of lung tumor angiogenesis: Insights and innovations

机译：肺肿瘤血管生成的影像学评估：见解和创新

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Lung cancer is the leading cause of cancer death in the United States. It is estimated that more than 228,000 new cases will be diagnosed in 2013, accounting for approximately 159,000 or 27% of all cancer deaths. Survival in these patients remains poor despite advances in surgery, definitive radiotherapy, and chemotherapy for primary and metastatic non-small cell lung cancer. Five-year relative survival rates remain at 27% for regional disease and 54% for node-negative disease. With the increasing personalization of therapy, there remains a need for better prognostic and predictive markers to direct patient management in lung cancer. Hypoxia and angiogenesis play an important role in the development and progression of lung cancer. Targeted and non-targeted imaging techniques in the preclinical and clinical setting, combined with advanced postprocessing techniques to assess tumor heterogeneity, may enable clinicians to better characterize lung tumors, and to predict and assess response to treatment. In this review, we summarize our current understanding of angiogenesis in lung cancer and discuss the available imaging techniques to assess this in the preclinical and clinical setting.
机译：肺癌是美国癌症死亡的主要原因。据估计，2013年将诊断出228,000多例新病例，约占159,000例，占所有癌症死亡人数的27％。尽管在原发性和转移性非小细胞肺癌的手术，确定性放疗和化学疗法方面取得了进步，但这些患者的生存仍然很差。区域性疾病的五年相对存活率仍为27％，淋巴结阴性疾病的为54％。随着疗法的个性化程度的提高，仍然需要更好的预后和预测指标来指导肺癌患者的治疗。缺氧和血管生成在肺癌的发生和发展中起重要作用。临床前和临床环境中的靶向和非靶向成像技术，结合先进的后处理技术来评估肿瘤异质性，可以使临床医生更好地表征肺部肿瘤，并预测和评估对治疗的反应。在这篇综述中，我们总结了我们目前对肺癌血管生成的理解，并讨论了可用于评估其在临床前和临床环境中的影像学技术。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号